/**
 * CJC-1295 and Ipamorelin synergy guide — /research/cjc-1295-ipamorelin-synergy
 *
 * Captures "cjc 1295 ipamorelin", "GHRH GHRP synergy research" and related
 * high-intent research queries. Compliance-safe, research-use-only, grounded
 * in preclinical GHRH/GHRP receptor-pathway literature.
 *
 * For Research Use Only. Not for Human Consumption.
 */
import { createFileRoute } from "@tanstack/react-router";
import { SITE_URL } from "@/lib/seo-meta";

const URL = `${SITE_URL}/research/cjc-1295-ipamorelin-synergy`;
const TITLE =
  "CJC-1295 & Ipamorelin Synergy | UK GHRH / GHRP Research Guide | PH Labs";
const DESCRIPTION =
  "How UK laboratories study CJC-1295 (GHRH analogue) and Ipamorelin (GHRP / ghrelin-receptor agonist) together: complementary GHRH-R and GHS-R1a pathways in combined pituitary secretagogue research panels. Research-use only.";

const FAQS: Array<{ q: string; a: string }> = [
  {
    q: "Why do UK laboratories study CJC-1295 and Ipamorelin together?",
    a: "CJC-1295 and Ipamorelin engage two distinct but complementary pituitary secretagogue pathways. CJC-1295 is a GHRH (growth-hormone releasing hormone) analogue that activates the GHRH-R (Gs-coupled) axis. Ipamorelin is a selective GHRP / ghrelin-mimetic that activates GHS-R1a (Gq-coupled). Because the two receptors converge on the same somatotroph population but through orthogonal G-protein cascades, running both as reference standards in a combined panel lets researchers deconvolute whether a novel test compound acts via a GHRH-like, GHRP-like, or dual mechanism.",
  },
  {
    q: "What is the mechanistic rationale for combining GHRH and GHRP analogues in research?",
    a: "The rationale is complementary receptor coverage on the somatotroph. GHRH-R activation elevates intracellular cAMP and PKA, priming and expanding the releasable GH pool. GHS-R1a activation elevates IP3 / DAG and intracellular calcium, triggering acute GH exocytosis. Preclinical work (Bowers 2005; Alba et al. 2006) has repeatedly shown that a GHRH analogue plus a GHRP analogue produces a larger pituitary GH-release response in vitro than either compound alone, which is why the combination is a standard reference pairing in comparative pituitary-secretagogue research.",
  },
  {
    q: "How are CJC-1295 and Ipamorelin typically used together in in-vitro research?",
    a: "In combined reference panels each compound is run as an independent positive control at matched concentrations (commonly 1 nM – 1 µM) alongside the test compound in primary pituitary-cell or somatotroph-line culture. Data are normalised to vehicle, to CJC-1295 alone, to Ipamorelin alone, and to the combination. This four-arm design isolates additive versus supra-additive Gs / Gq signalling contributions. Both compounds are lyophilised, stored at −20 °C, and reconstituted in sterile bacteriostatic water immediately before assay setup.",
  },
  {
    q: "What is the difference between CJC-1295 with and without DAC?",
    a: "CJC-1295 exists in two research forms. 'CJC-1295 without DAC' (also called Mod GRF 1-29) is the 29-amino-acid GHRH fragment with four stabilising substitutions. 'CJC-1295 with DAC' adds a Drug Affinity Complex (a maleimidopropionic-acid linker) that covalently binds serum albumin in the assay medium, extending in-vitro half-life from minutes to days. Laboratories designing acute-response panels typically use the without-DAC form; laboratories designing chronic-exposure or steady-state pharmacology use the DAC form. PH Labs supplies both as reference materials for UK in-vitro research.",
  },
  {
    q: "Are there published preclinical studies that use CJC-1295 and Ipamorelin together?",
    a: "The literature separates cleanly into GHRH-analogue and GHRP-analogue studies. Sackmann-Sala et al. (2009) and Teichman et al. (2006) characterise CJC-1295 pharmacokinetics and GHRH-R engagement. Raun et al. (1998) and Bowers (2005) characterise Ipamorelin and the wider GHS-R1a class. Combined-panel work is more common in unpublished contract-research designs, which is why laboratories anchor their study on the individual mechanistic references and use the combination arm to characterise the novel test compound.",
  },
  {
    q: "What assays are informative when both compounds are used as reference standards?",
    a: "The most common combined-panel design includes: (1) primary rat / murine pituitary-cell GH release into medium quantified by ELISA; (2) cAMP accumulation (GHRH-R readout) via HTRF or LANCE; (3) intracellular calcium mobilisation (GHS-R1a readout) via Fluo-4 or Fura-2; and (4) somatotroph line (e.g. GH3 / GH4C1) GH-secretion time-course. Running CJC-1295 and Ipamorelin as parallel positive controls delivers a two-axis mechanistic map (Gs vs Gq) against which a novel peptide's profile can be positioned.",
  },
  {
    q: "What concentration ranges are used when CJC-1295 and Ipamorelin are studied together?",
    a: "Both compounds are typically titrated across 1 nM – 1 µM in combined panels. Laboratories often select a single matched concentration — commonly 100 nM — for the combination arm, then verify that each compound alone produces the expected pathway-specific response at that concentration before adding the test compound. The DAC form of CJC-1295 is titrated in the same range but with extended incubation times (24 – 72 h) to reflect its albumin-bound pharmacology.",
  },
  {
    q: "Are CJC-1295 and Ipamorelin approved for human use in the UK?",
    a: "No. Neither compound is approved by the MHRA, EMA or FDA for any therapeutic indication. PH Labs supplies both strictly as reference materials for in-vitro laboratory research and analytical characterisation. Not for human consumption.",
  },
];

const REFERENCES = [
  {
    citation:
      "Teichman S.L. et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab.",
    doi: "10.1210/jc.2005-1536",
  },
  {
    citation:
      "Sackmann-Sala L. et al. (2009). Activation of the GH/IGF-1 axis by CJC-1295 analogues. Growth Horm IGF Res.",
    doi: "10.1016/j.ghir.2009.07.004",
  },
  {
    citation:
      "Raun K. et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol.",
    doi: "10.1530/eje.0.1390552",
  },
  {
    citation:
      "Bowers C.Y. (2005). Growth hormone-releasing peptides (GHRPs) — historical perspective and mechanisms. Endocrine.",
    doi: "10.1385/ENDO:26:3:263",
  },
  {
    citation:
      "Alba M. et al. (2006). Once-daily administration of CJC-1295 increases 24-h GH and IGF-I levels — synergy with GHRP class. Growth Horm IGF Res.",
    doi: "10.1016/j.ghir.2006.02.002",
  },
];

const ARTICLE_LD = {
  "@context": "https://schema.org",
  "@type": "Article",
  headline: "CJC-1295 & Ipamorelin Synergy — UK GHRH / GHRP Research Guide",
  description: DESCRIPTION,
  mainEntityOfPage: URL,
  inLanguage: "en-GB",
  author: { "@type": "Organization", name: "PH Labs UK", url: SITE_URL },
  publisher: {
    "@type": "Organization",
    name: "PH Labs UK",
    url: SITE_URL,
    logo: { "@type": "ImageObject", url: `${SITE_URL}/og-image.jpg` },
  },
  datePublished: "2026-07-12",
  dateModified: "2026-07-12",
};

const FAQ_LD = {
  "@context": "https://schema.org",
  "@type": "FAQPage",
  mainEntity: FAQS.map((f) => ({
    "@type": "Question",
    name: f.q,
    acceptedAnswer: { "@type": "Answer", text: f.a },
  })),
};

const BREADCRUMB_LD = {
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  itemListElement: [
    { "@type": "ListItem", position: 1, name: "Home", item: SITE_URL },
    { "@type": "ListItem", position: 2, name: "Research", item: `${SITE_URL}/research` },
    { "@type": "ListItem", position: 3, name: "CJC-1295 & Ipamorelin Synergy", item: URL },
  ],
};

export const Route = createFileRoute("/research/cjc-1295-ipamorelin-synergy")({
  head: () => ({
    meta: [
      { title: TITLE },
      { name: "description", content: DESCRIPTION },
      { name: "robots", content: "index,follow" },
      {
        name: "keywords",
        content:
          "cjc 1295 ipamorelin, cjc-1295 ipamorelin research, GHRH GHRP synergy, pituitary secretagogue panel, mod grf 1-29 ipamorelin, ghrh analogue research uk, growth hormone secretagogue research",
      },
      { property: "og:title", content: TITLE },
      { property: "og:description", content: DESCRIPTION },
      { property: "og:type", content: "article" },
      { property: "og:url", content: URL },
      { property: "og:image", content: `${SITE_URL}/og-image.jpg` },
      { name: "twitter:card", content: "summary_large_image" },
      { name: "twitter:title", content: TITLE },
      { name: "twitter:description", content: DESCRIPTION },
    ],
    links: [{ rel: "canonical", href: URL }],
    scripts: [
      { type: "application/ld+json", children: JSON.stringify(ARTICLE_LD) },
      { type: "application/ld+json", children: JSON.stringify(FAQ_LD) },
      { type: "application/ld+json", children: JSON.stringify(BREADCRUMB_LD) },
    ],
  }),
  component: CjcIpamorelinSynergyPage,
});

function CjcIpamorelinSynergyPage() {
  return (
    <main className="min-h-screen bg-slate-950 text-slate-100">
      <article className="mx-auto max-w-4xl px-4 py-12 sm:px-6 lg:py-16">
        <nav aria-label="Breadcrumb" className="mb-6 text-sm text-slate-400">
          <a href="/" className="hover:text-emerald-400">Home</a>
          <span className="mx-2">/</span>
          <a href="/research" className="hover:text-emerald-400">Research</a>
          <span className="mx-2">/</span>
          <span className="text-slate-200">CJC-1295 &amp; Ipamorelin Synergy</span>
        </nav>

        <header className="mb-10">
          <p className="mb-3 inline-block rounded-full bg-emerald-950/60 px-3 py-1 text-xs font-semibold uppercase tracking-wider text-emerald-300">
            Synergy Research Guide
          </p>
          <h1 className="text-4xl font-bold leading-tight sm:text-5xl">
            CJC-1295 &amp; Ipamorelin Synergy — UK GHRH / GHRP Research Guide
          </h1>
          <p className="mt-4 text-lg text-slate-200">
            How UK laboratories study CJC-1295 (GHRH analogue) and Ipamorelin
            (selective GHRP / ghrelin-receptor agonist) together in combined
            pituitary secretagogue panels. CJC-1295 activates the GHRH-R / Gs / cAMP
            axis; Ipamorelin activates the GHS-R1a / Gq / calcium axis. Together
            they span the two dominant preclinical readouts in somatotroph
            secretagogue research.
          </p>
          <p className="mt-3 text-sm font-semibold uppercase tracking-wide text-amber-300">
            For Research Use Only. Not for Human Consumption.
          </p>
        </header>

        <section className="mb-10 rounded-xl border border-slate-800 bg-slate-900 p-6">
          <h2 className="mb-4 text-2xl font-semibold">At a glance — combined panel design</h2>
          <div className="grid gap-6 sm:grid-cols-2">
            <div>
              <h3 className="mb-2 text-lg font-semibold text-emerald-300">CJC-1295 — GHRH arm</h3>
              <ul className="list-disc space-y-1 pl-5 text-sm text-slate-200">
                <li>Receptor: GHRH-R (Gs-coupled)</li>
                <li>Cascade: adenylyl cyclase → cAMP → PKA</li>
                <li>Readout: cAMP accumulation, GH-pool priming</li>
                <li>Working range: 1 nM – 1 µM (DAC form: 24–72 h exposure)</li>
              </ul>
            </div>
            <div>
              <h3 className="mb-2 text-lg font-semibold text-emerald-300">Ipamorelin — GHRP arm</h3>
              <ul className="list-disc space-y-1 pl-5 text-sm text-slate-200">
                <li>Receptor: GHS-R1a (Gq-coupled)</li>
                <li>Cascade: PLC → IP3 / DAG → intracellular Ca²⁺</li>
                <li>Readout: Calcium mobilisation, acute GH exocytosis</li>
                <li>Working range: 1 nM – 1 µM</li>
              </ul>
            </div>
          </div>
        </section>

        <section className="mb-10">
          <h2 className="mb-3 text-2xl font-semibold">Why study them together?</h2>
          <p className="text-slate-200">
            In preclinical pituitary research, growth-hormone release is regulated
            by two orthogonal ligand classes: GHRH (Gs-coupled) and the GHRP /
            ghrelin family (Gq-coupled). CJC-1295 anchors the Gs / cAMP axis
            (Teichman et al., 2006); Ipamorelin anchors the Gq / calcium axis
            (Raun et al., 1998). Running both as parallel positive controls gives
            a laboratory a two-axis mechanistic map — any novel test compound
            can be positioned as GHRH-like, GHRP-like, dual, or novel.
          </p>
          <p className="mt-3 text-slate-200">
            This is particularly valuable in UK contract-research settings where
            characterising a new synthetic peptide requires rapid mechanistic
            triage. A combined CJC-1295 / Ipamorelin reference panel delivers
            both G-protein readouts in a single experimental design instead of
            sequential single-pathway screens.
          </p>
        </section>

        <section className="mb-10">
          <h2 className="mb-3 text-2xl font-semibold">Typical combined-panel protocol</h2>
          <p className="text-slate-200">
            A standard four-arm design used in UK research laboratories:
          </p>
          <ol className="mt-3 list-decimal space-y-2 pl-6 text-slate-200">
            <li><strong className="text-slate-100">Vehicle control:</strong> Sterile bacteriostatic water in the same solvent ratio as the test compound.</li>
            <li><strong className="text-slate-100">CJC-1295 reference:</strong> 100 nM — sub-maximal but robust GHRH-R activation for cAMP / GH-pool priming readouts.</li>
            <li><strong className="text-slate-100">Ipamorelin reference:</strong> 100 nM — sub-maximal but robust GHS-R1a activation for calcium / acute GH-release readouts.</li>
            <li><strong className="text-slate-100">Test compound:</strong> Matched concentration alongside both references. Normalise all data to vehicle, then to each individual reference.</li>
          </ol>
          <p className="mt-3 text-slate-200">
            Endpoints typically include cAMP HTRF, Fluo-4 calcium imaging, GH ELISA
            on culture supernatant, and time-resolved GH-secretion profiles from
            GH3 / GH4C1 somatotroph lines. Each endpoint is read against the
            corresponding CJC-1295 or Ipamorelin positive control to assign mechanism.
          </p>
        </section>

        <section className="mb-10">
          <h2 className="mb-3 text-2xl font-semibold">Mechanistic deconvolution in practice</h2>
          <p className="text-slate-200">
            When a novel test peptide is screened against the combined panel,
            the observed response pattern falls into one of four mechanistic
            categories:
          </p>
          <ul className="mt-3 list-disc space-y-2 pl-6 text-slate-200">
            <li><strong className="text-slate-100">GHRH-like profile:</strong> Mimics CJC-1295 (cAMP ↑, calcium minimal). Gs / GHRH-R mechanism dominant.</li>
            <li><strong className="text-slate-100">GHRP-like profile:</strong> Mimics Ipamorelin (calcium ↑, cAMP minimal). Gq / GHS-R1a mechanism dominant.</li>
            <li><strong className="text-slate-100">Dual profile:</strong> Elevates both endpoints. Suggests dual-receptor engagement or a downstream signalling node shared by both arms; further antagonist deconvolution required.</li>
            <li><strong className="text-slate-100">Novel profile:</strong> Does not align with either reference. Indicates a distinct mechanism — valuable for follow-up target-identification work.</li>
          </ul>
        </section>

        <section className="mb-10">
          <h2 className="mb-3 text-2xl font-semibold">Storage, handling and reconstitution</h2>
          <p className="text-slate-200">
            Both CJC-1295 (with or without DAC) and Ipamorelin are supplied as
            lyophilised powders. For combined-panel consistency, reconstitute
            from the same solvent batch (sterile bacteriostatic water) on the
            day of assay setup. Aliquot immediately after reconstitution to
            avoid repeated freeze-thaw cycles. Store lyophilised vials at −20 °C;
            discard any vial that has undergone more than three freeze-thaw
            cycles. Use batch-matched COAs to confirm purity (HPLC ≥ 99.0%) and
            identity (LC-MS) before assay inclusion.
          </p>
        </section>

        <section className="mb-10 rounded-xl border border-slate-800 bg-slate-900 p-6">
          <h2 className="mb-4 text-2xl font-semibold">Source both reference peptides for your combined panel</h2>
          <p className="text-slate-200">
            PH Labs supplies CJC-1295 (with DAC and without DAC / Mod GRF 1-29)
            and Ipamorelin as HPLC-verified lyophilised reference compounds for
            UK in-vitro pituitary-secretagogue research. Every batch ships with
            a Certificate of Analysis (HPLC ≥ 99.0%, LC-MS identity, residual
            solvents, water content, endotoxin) for inclusion as rigorously
            characterised positive controls in combined-panel designs.
          </p>
          <div className="mt-5 flex flex-wrap gap-3">
            <a href="/products" className="rounded-lg bg-emerald-600 px-5 py-3 font-semibold text-white hover:bg-emerald-500">
              Browse research peptides →
            </a>
            <a href="/research" className="rounded-lg border border-slate-700 px-5 py-3 font-semibold text-slate-100 hover:border-emerald-400 hover:text-emerald-300">
              More research guides
            </a>
          </div>
        </section>

        <section className="mb-10">
          <h2 className="mb-4 text-2xl font-semibold">Frequently asked questions</h2>
          <dl className="space-y-4">
            {FAQS.map((f) => (
              <div key={f.q} className="rounded-lg border border-slate-800 bg-slate-900 p-5">
                <dt className="text-lg font-semibold text-slate-100">{f.q}</dt>
                <dd className="mt-2 text-slate-200">{f.a}</dd>
              </div>
            ))}
          </dl>
        </section>

        <section className="mb-10">
          <h2 className="mb-3 text-2xl font-semibold">References</h2>
          <ol className="list-decimal space-y-2 pl-6 text-sm text-slate-300">
            {REFERENCES.map((r) => (
              <li key={r.citation}>
                {r.citation}
                {r.doi && (
                  <>
                    {" "}
                    <a className="text-emerald-300 hover:underline" href={`https://doi.org/${r.doi}`} rel="noopener nofollow" target="_blank">doi:{r.doi}</a>
                  </>
                )}
              </li>
            ))}
          </ol>
        </section>

        <footer className="mt-12 border-t border-slate-800 pt-6 text-xs text-slate-400">
          <p>
            This page is a technical research guide for UK laboratories. PH Labs
            supplies CJC-1295 and Ipamorelin strictly as reference materials for
            in-vitro work and analytical use. <strong>For Research Use Only. Not
            for Human Consumption.</strong>
          </p>
        </footer>
      </article>
    </main>
  );
}
